MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by SciSparc Ltd

< Previous 1 2 3 4 Next >
News headline image
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
SciSparc Receives Final Approval to Commence its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million
From SciSparc Ltd
Via GlobeNewswire
Tickers JFBR SPRC
News headline image
SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US
From SciSparc Ltd
Via GlobeNewswire
Tickers CMND CSE:CMND SPRC
News headline image
SciSparc Announces Corporate Restructuring plan
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
News headline image
SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment
From SciSparc Ltd
Via GlobeNewswire
Tickers SPRC
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story